A recent blog post on Tribeca Knowledge outlines some of the key challenges pharmaceutical companies face regarding drug launches in the midst of the COVID-19 pandemic.
Drug launches outside the COVID-19 arena “are under threat of delay, postponement, dilution or worse,” the author, Andre Moa, writes.
“This is at a time when patient needs have lost none of their urgency, especially for people with serious conditions such as cancer, cardiovascular disease or asthma,” Moa writes. “They are made all the more vulnerable by increased susceptibility to viral infection and the diversion of hard-pressed healthcare resources to contain the pandemic.”
To read the full blog post, click here.